Neisseria meningitidis Infections - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 104 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2016, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 3, 2, 3, 8 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 2, 1, 5 and 1 molecules, respectively for Neisseria meningitidis Infections.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Neisseria meningitidis Infections Overview 10
Therapeutics Development 11
Pipeline Products for Neisseria meningitidis Infections - Overview 11
Pipeline Products for Neisseria meningitidis Infections - Comparative Analysis 12
Neisseria meningitidis Infections - Therapeutics under Development by Companies 13
Neisseria meningitidis Infections - Therapeutics under Investigation by Universities/Institutes 14
Neisseria meningitidis Infections - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Neisseria meningitidis Infections - Products under Development by Companies 18
Neisseria meningitidis Infections - Products under Investigation by Universities/Institutes 20
Neisseria meningitidis Infections - Companies Involved in Therapeutics Development 21
Beijing Minhai Biotechnology Co., Ltd 21
Beijing Tiantan Biological Products Co., Ltd. 22
Biological E. Limited 23
China National Pharmaceutical Group Corporation 24
GlaxoSmithKline Plc 25
ImmunoBiology Limited 26
JN-International Medical Corporation 27
MGB Biopharma Limited 28
Panacea Biotec Limited 29
Pfizer Inc. 30
Sanofi Pasteur SA 31
Serum Institute of India Limited 32
Wellstat Vaccines, LLC 33
Neisseria meningitidis Infections - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
(meningococcal + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
MenBioVax - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
meningococcal (tetravalent) vaccine - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
meningococcal [serotype B] vaccine - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
meningococcal [serotype B] vaccine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
meningococcal [serotype B] vaccine - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
meningococcal [serotype B] vaccine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
meningococcal [serotype B] vaccine - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
meningococcal [serotype B] vaccine - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
meningococcal [serotype B] vaccine - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
meningococcal [serotypes A, C, W135] vaccine - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
meningococcal [serotypes A, C] vaccine - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
meningococcal [serotypes C, Y] vaccine - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
meningococcal [strain C2135] vaccine - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
meningococcal vaccine - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
meningococcal vaccine - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
meningococcal vaccine 2 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
MGBBP-3 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Neisseria meningitidis [serotype B] vaccine - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Neisseria meningitidis [serotype B] vaccine - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Nimenrix - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
TP-10 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Neisseria meningitidis Infections - Dormant Projects 88
Neisseria meningitidis Infections - Discontinued Products 90
Neisseria meningitidis Infections - Product Development Milestones 91
Featured News & Press Releases 91
Sep 05, 2016: 'Real world' data shows 83 percent effectiveness for Bexsero in infants in first year of UK national meningitis B immunisation programme 91
May 20, 2016: Pfizer Announces European Medicines Agency Acceptance For Review Of Marketing Authorization Application For TRUMENBA (Meningococcal Group B Vaccine) 92
May 13, 2016: GSK's Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children 92
May 13, 2016: Pfizer Presents Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting 93
Oct 09, 2015: Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents 95
Aug 21, 2015: Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine) 96
Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age 97
Jun 24, 2015: U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines 97
May 01, 2015: GSK launches first vaccine to prevent meningococcal disease caused by meningococcus B in Brazil 98
Mar 29, 2015: GSK statement on meningitis vaccination in the UK 98
Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk 99
Feb 24, 2015: Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis Vaccines In Adolescents 100
Jan 23, 2015: FDA approves a second vaccine to prevent serogroup B meningococcal disease 101
Dec 24, 2014: Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial 102
Nov 18, 2014: TRUMENBA (Meningococcal Group B Vaccine) is Now Available 102
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 103
Disclaimer 104

List of Tables

Number of Products under Development for Neisseria meningitidis Infections, H2 2016 11
Number of Products under Development for Neisseria meningitidis Infections - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2016 20
Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 21
Neisseria meningitidis Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016 22
Neisseria meningitidis Infections - Pipeline by Biological E. Limited, H2 2016 23
Neisseria meningitidis Infections - Pipeline by China National Pharmaceutical Group Corporation, H2 2016 24
Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 25
Neisseria meningitidis Infections - Pipeline by ImmunoBiology Limited, H2 2016 26
Neisseria meningitidis Infections - Pipeline by JN-International Medical Corporation, H2 2016 27
Neisseria meningitidis Infections - Pipeline by MGB Biopharma Limited, H2 2016 28
Neisseria meningitidis Infections - Pipeline by Panacea Biotec Limited, H2 2016 29
Neisseria meningitidis Infections - Pipeline by Pfizer Inc., H2 2016 30
Neisseria meningitidis Infections - Pipeline by Sanofi Pasteur SA, H2 2016 31
Neisseria meningitidis Infections - Pipeline by Serum Institute of India Limited, H2 2016 32
Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines, LLC, H2 2016 33
Assessment by Monotherapy Products, H2 2016 34
Assessment by Combination Products, H2 2016 35
Number of Products by Stage and Target, H2 2016 37
Number of Products by Stage and Mechanism of Action, H2 2016 38
Number of Products by Stage and Route of Administration, H2 2016 40
Number of Products by Stage and Molecule Type, H2 2016 42
Neisseria meningitidis Infections - Dormant Projects, H2 2016 88
Neisseria meningitidis Infections - Dormant Projects (Contd..1), H2 2016 89
Neisseria meningitidis Infections - Discontinued Products, H2 2016 90